There is no mutation enrichment in regions encoding the JMJD6 catalytic center or in particular cancer types with the exception of the aforementioned breast cancer and neuroendocrine prostate cancer samples (Supplementary Figure S2). Here, JMJD6 is linked to breast carcinoma.